This study maps the global clinical trial landscape of cytokine-induced killer (CIK) cell therapy across malignancies and selected immune-related disorders, based on 199 interventional trials retrieved from the Informa database up to February 2026. An…
The results of a recent comprehensive investigation—confirmed in multiple cohorts—show that patients with hepatocellular carcinoma, who favorably responded to anti-programmed cell death protein 1 (PD-1) therapy, were enriched in IgG1-produ…
Retlirafusp alfa (SHR-1701), a bifunctional programmed death-ligand 1 (PD-L1) antibody fused to a TGF-β trap, was approved in China on January 7, 2026 for first-line treatment of PD-L1-positive advanced gastric or gastroesophageal junction adenoc…
Current T-cell-based immunotherapies—chimeric antigen receptor T (CAR-T) cells, checkpoint inhibitors, and neoantigen vaccines—share a fundamental vulnerability: they target fixed antigens while tumors continuously evolve. Like influenza v…
Approximately one-third of patients with metastatic triple-negative breast cancer (TNBC) develop brain metastases during their lifetime. Notably, up to 90% of TNBC brain metastases express B7-H3, a molecule that contributes to an immunosuppressive mic…
A recent study by Grippin et al showed that COVID-19 mRNA-lipid nanoparticle vaccines can be strategically implemented to fundamentally reshape the immunosuppressive tumor microenvironment and boost the efficacy of immune checkpoint inhibitors (ICIs) …
Maintenance of anticancer immunity without compromising immune tolerance remains a challenge. Immunosuppressive regulatory T cells (Tregs) are the guardians of immune tolerance that underpin prevention of autoimmune responses. Tregs express checkpoint…
Local immunotherapy has the potential to deliver high doses of immune-potentiating agents with limited systemic toxicity. However, clinical development and implementation have been hindered by numerous challenges. Journal for ImmunoTherapy of Cancer w…
Accumulating evidence from randomized phase 3 trials in multiple tumor types supports the application of neoadjuvant or perioperative immunotherapy to significantly enhance clinical benefit in patients with resectable solid tumors. While systemic immu…
Checkpoint blockade immunotherapy has changed the landscape of cancer treatment for many types of malignancies, but it still does not work for all individuals and for all tumor types. Much work over the past decade has been dedicated to discerning wha…
